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Purpose: To gain a better understanding of the roles of interleukins (ILs) in subconjunctival fibrosis, we investigated
their expression in transforming growth factor-β1 (TGF-β1)-stimulated Tenon’s fibroblasts and examined their association
with the transdifferentiation of fibroblasts to myofibroblasts.
Methods:  After  primary  culture,  fibroblasts  derived  from  human  Tenon’s  capsule  were  exposed  to  TGF-β1.  The
expression of α-smooth muscle actin (α-SMA) protein was assessed by western immunoblots and immunofluorescence.
The mRNA levels of various ILs were also evaluated by multiplex reverse transcription (RT)-PCR. Using the small
interfering RNAs (siRNAs) specific for IL-6 and IL-11 and the promoter deletion assay, the contributions of IL-6 and IL-11
to TGF-β1-induced induction of α-SMA were determined.
Results: In human Tenon’s fibroblasts, TGF-β1 stimulated the expression of α-SMA protein determined by western blot
analysis and also increased the mRNA levels of IL-6 and IL-11 determined by multiplex RT-PCR. On the western
immunoblots and immunofluorescence, the increased expression of α-SMA was attenuated only by the siRNAs specific for
IL-6 but not by the siRNAs specific for IL-11. When the activator protein-1 binding sites of the IL-6 promoter region were
deleted, the stimulation effects of TGF-β1 decreased.
Conclusions: Our data show that autocrine IL-6 may participate in the TGF-β1-induced transdifferentiation of human
Tenon’s fibroblasts to myofibroblasts, which is known to be an essential step for subconjunctival fibrosis.
Subconjunctival fibrosis is an essential wound-healing
process of the ocular surface, but if excessive it can result in
ocular morbidity, as seen in patients with oculocutaneous
disorders, such as ocular cicatricial pemphigoid, and patients
who have undergone glaucoma-filtering surgery [1-6]. Even
though transforming growth factor-β (TGF-β) is known to
play a crucial role in this fibrosis [7-9], detailed mechanisms
of how it functions have not yet been elucidated. Several
recently  published  research  papers  that  demonstrated
antifibrotic  effects  of  anti-TGF-β  molecules  have  re-
stimulated interest in TGF-β-mediated fibrosis [10-14].
In the present study, we were interested in investigating
the relationship between inflammation and fibrosis in human
Tenon’s  fibroblasts.  In  lung  and  heart,  certain  types  of
inflammation recruit and stimulate fibroblasts in a TGF-β-
dependent manner [15-18]. These activated fibroblasts then
transdifferentiate to myofibroblasts that produce extracellular
matrix  (ECM);  these  contractile  cells  ultimately  cause
extensive fibrosis. In this study we investigated which of the
proinflammatory cytokines of the interleukin (IL) family are
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stimulated  by  TGF-β1,  and  we  monitored  changes  in  α-
smooth  muscle  actin  (α-SMA),  a  phenotypic  hallmark  of
myofobroblasts [19], to investigate the effect of the TGF-β1-
stimulated ILs on the transdifferentiation of fibroblasts to
myofibroblasts. The effects of blocking these ILs with small
interfering RNA (siRNA) were also investigated.
METHODS
Cell culture: After obtaining approval from the Institutional
Review Board of our institution, 6 human Tenon’s capsule
specimens  were  excised  during  strabismus  surgeries  in
compliance with the provisions of the Declaration of Helsinki.
A total of six participants who have no other disease except
strabismus  and  no  previous  ocular  surgery/trauma  history
were included. Written informed consent was obtained before
operative  excision.  Briefly,  5x5-mm  sections  of  Tenon’s
capsule were collected, minced, and placed in a 35-mm culture
dish  containing  Dulbecco’s  modified  Eagle’s  medium
(DMEM; Invitrogen Co., Carlsbad, CA) supplemented with
10% fetal calf serum (Invitrogen), and 50 U/ml penicillin and
50 μg/ml streptomycin (Invitrogen). Cells were allowed to
migrate from the explanted tissue and were then incubated at
37 °C and 5% CO2. Cells between the third and fifth passages
were used for this study. Cultures were allowed to reach about
80% confluence. Depending on the experiments, fibroblasts
were treated with various concentrations of TGF-β1 (R&D
Molecular Vision 2009; 15:2123-2128 <http://www.molvis.org/molvis/v15/a228>
Received 28 July 2009 | Accepted 16 October 2009 | Published 21 October 2009
© 2009 Molecular Vision
2123System, Minneapolis, MN) after 24 h of serum starvation in
serum-free DMEM.
Western immunoblot analysis: Whole cellular proteins were
isolated from primary cultured fibroblasts of human Tenon’s
capsules,  as  described  previously  [20].  Briefly,  total  cell
lysates were obtained by using lysis buffer (25 mM HEPES
[pH 7.5], 0.3 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.05%
Triton  X-100,  0.5  mM  dithiothreitol  [DTT],  and  0.4  mM
phenylmethylsulfonyl fluoride [PMSF]; Sigma-Aldrich, Co.,
St. Louis, MO), 2 μg/ml leupeptin (Sigma-Aldrich), and 2
μg/ml aprotinin (Sigma-Aldrich). Equal amounts of protein
(20  μg)  were  subjected  to  sodium  dodecyl  sulfate
polyacrylamide  gel  electrophoresis  and  transferred  to
nitrocellulose  membranes.  Membranes  were  probed  with
primary  antibodies  against  human  α-SMA  (diluted  1:500;
Dako  Corporation,  Carpinteria,  CA)  and  β-actin  (diluted
1:5,000; Santa Cruz Biotechnology, Inc., Santa Cruz, CA).
Immunoreactive  bands  were  detected  with  horseradish
peroxidase-conjugated secondary antibodies (diluted 1:5,000;
Invitrogen) and visualized by enhanced chemiluminescence
detection reagents on autoradiograph films.
Multiplex  reverse  transcription-PCR:  Total  RNA  was
extracted from fibroblasts and converted into complementary
(c)DNA by a first-strand synthesis system (SuperScript III;
Invitrogen). Subsequently, the cDNA was used as a template
for  multiplex  reverse  transcription  (RT)-PCR  assays
(MegaXpression; Seegene, Inc., Seoul, Korea) [21,22]. The
following IL gene segments were amplified: IL-1α, IL-1β,
IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11,
IL-12A, IL-12B, IL-13, IL-15, IL-16, IL-18, and IL-1 receptor
antagonist (IL-1RN). In addition, gene segments of β-actin,
β2-microblobulin  (β2M),  glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), succinate dehydrogenase complex
subunit A (SDHA), and ribosomal protein L13a (RPL13a)
were amplified as housekeeping genes.
RNA interference assay: siRNA molecules targeting IL-6 and
IL-11 mRNA were purchased from Ambion, Inc. (Austin,
TX). The RNA duplex against IL-6 had the sequence 5'-GGA
CAU GAC AAC UCA UCU CTT-3' (sense) and 5'-GAG
AUG AGU UGU CAU GUC CTG-3' (antisense); and the
RNA duplex against IL-11 had the sequence 5'-GCA ACA
UGG UGC AUC UGU GTT-3' (sense) and 5'-CAC AGA
UGC  ACC  AUG  UUG  CTT-3'  (antisense).  siRNAs  were
delivered  into  cells  according  to  the  manufacturer’s
instructions. Briefly, the diluted transfection reagent (siPORT
Amine; Ambion) was mixed with the diluted siRNA to allow
the formation of transfection complexes. This mixture with a
final RNA concentration of 20 nM was then dispensed onto
the cells and incubated for 24 h.
Immunofluorescence analysis: To carry out immunostaining,
fibroblasts were fixed in 4% paraformaldehyde for 5 min and
permeabilized  in  0.2%  Triton  X-100  for  5  min  at  room
temperature. Fibroblasts were then incubated with the primary
antibody against human α-SMA (diluted 1:50) overnight at 4
°C and probed with a fluoroscein isothiocyanate-conjugated
secondary  antibody  (diluted  1:100)  for  2  h  at  room
temperature in the dark. Subsequently, they were washed and
viewed by immunofluorescence microscopy (IX71; Olympus,
Tokyo, Japan).
Cell transfection and luciferase assay: Three recombinant
plasmids,  in  which  different  fragments  of  the  activator
protein-1 (AP-1)-binding site of the human IL-6 promoter
were  deleted  (p1168hu.IL6P-luc+,  wild  type;
p1168h.IL6m3AP1-luc+,  3'-terminal  deletion;  and
p1168h.IL6m5AP1-luc+, 5'-terminal deletion), were used as
reporter constructs. These plasmids were obtained from the
Belgian Coordinated Collections of Microorganism (BCCM/
LMBP) Plasmid Collection (Zwijnaarde, Belgium) and have
been described previously [23,24].
Cells were transfected with an equal amount of reporter
plasmid  using  Lipofectamine  2000  (Invitrogen).  The
luciferase activities were determined using a luciferase assay
system  (Promega,  Co.,  Madison,  WI),  following  the
manufacturer’s  instruction.  Briefly,  the  96-well  plate
containing 20 μl of cell lysate per well was placed into the
luminometer  with  injector.  The  injector  added  100  μl  of
luciferase  assay  reagent  per  well,  then  the  well  was  read
immediately. The plate was advanced to the next well for a
repeat of the inject-then-read process. The typical delay time
was 2 s and the typical read time was 10 s.
Data analysis: Densitometric data are expressed as means ±
standard deviation (SD). Data were compared with Kruskal-
Wallis one-way analysis of variance and Mann-Whitney U
test using the SPSS program for Windows, version 12.0.1
(SPSS  Inc.,  Chicago,  IL).  A  p  value  less  than  0.05  was
considered statistically significant.
RESULTS
Transforming growth factor-β1 induces transdifferentiation
of fibroblasts to myofibroblasts: To evaluate the effect of
TGF-β1 on the expression of α-SMA, we measured α-SMA
protein levels in human Tenon’s fibroblasts stimulated with
different concentrations of TGF-β1 for different durations.
Exposure of fibroblasts to TGF-β1 resulted in a dose- and
time-dependent increase in expression of α-SMA (Figure 1).
TGF-β1 treatment (10 ng/ml) for 72 h resulted in a significant
increase  (p<0.001)  in  α-SMA  expression.  Because  the
presence  of  α-SMA  is  a  phenotypic  hallmark  of
myofobroblasts, this finding indicates that TGF-β1 induced
the transdifferentiation of fibroblasts to myofibroblasts.
Upregulation  of  IL-6  and  IL-11  by  transforming  growth
factor-β1 treatment: To assess the effect of TGF-β1 on the
transcription of ILs, the IL mRNA levels in TGF-β1-treated
human Tenon’s fibroblasts were evaluated using multiplex
RT-PCR.  After  fibroblasts  were  incubated  with  10  ng/ml
TGF-β1 for 72 h, multiplex RT-PCR was performed. For the
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2124first set of genes (IL-1RN, IL-1α, IL-2, IL-3, IL-4, IL-5, and
IL-6), only IL-6 mRNA was increased significantly (p<0.001;
Figure 2A); for the second set of genes (IL-7, IL-10, IL-11,
IL-12B, IL-13, IL-15, and IL-16), only IL-11 mRNA was
increased significantly (p<0.001; Figure 2B). The levels of
IL-1β, IL-8, IL-9, IL-12A, and IL-18 were not changed (data
not shown) and the expression of β-actin, β2M, GAPDH,
SDHA, and RPL13a was not influenced by TGF-β1 (Figure
2C).  These  data  demonstrate  that  TGF-β1  induces  the
transcription of IL-6 and IL-11 in human Tenon’s fibroblasts.
Transforming  growth  factor-β1-induced  expression  of  α-
smooth  muscle  actin  is  reduced  by  IL-6-specific  small
interfering  RNAs:  To  more  directly  address  the  possible
involvement  of  IL-6  and  IL-11  in  TGF-β1-induced
myofibroblast transdifferentiation, we evaluated the effects of
IL-6 and IL-11 knockdown using specific siRNAs. Since the
accumulation  of  ECM  proteins  is  an  indicator  of
Figure 1. Representative western blot bands for α-smooth muscle
actin. A: Dose-response effects: fibroblasts were exposed to various
concentrations of transforming growth factor (TGF)-β1 for 72 h. B:
Time-response effects: fibroblasts were incubated with or without 10
ng/ml of TGF-β1 for up to 6 days. β-actin was used as an internal
control. Densitimetric data represent the mean±SD of results from
three independent experiments.
myofibroblast transdifferentiation, we studied the effect of
IL-6-  and  IL-11-specific  siRNAs  on  TGF-β1-induced
expression of the ECM component α-SMA. Treatment with
IL-6-specific siRNAs strongly inhibited the TGF-β1-induced
α-SMA  expression  (Figure  3A),  whereas  IL-11-specific
siRNAs had little effect (Figure 3B).
To confirm this finding, we assessed the effects of IL-6-
and  IL-11-specific  siRNAs  on  TGF-β1-induced  α-SMA
upregulation  by  immunofluorescent  staining  and  obtained
similar results with western immunoblot analysis (Figure 4).
Compared  to  untreated  control  fibroblasts,  TGF-β1-
stimulated fibroblasts showed a strong cytoplasmic α-SMA
signal with numerous intracellular stress fibers (Figure 4B).
Fibroblasts transfected with IL-6-specific siRNAs showed a
significant  reduction  in  the  effect  of  TGF-β1  on  α-SMA
expression (Figure 4D); but cytoplasmic staining for α-SMA
was little diminished in the presence of IL-11-specific siRNAs
(Figure 4F). These data demonstrate that knockdown of IL-6
reduces the ability of TGF-β1 to induce α-SMA expression.
Activator  protein-1  activity  at  the  IL-6  promoter  in  the
presence  of  transforming  growth  factor-β1:  To  determine
whether TGF-β1-mediated myofibroblast transdifferentiation
might be related to AP-1-binding site-dependent effects on
IL-6  transcription,  we  used  wild-type  and  mutant  IL-6
promoter-reporter  constructs  to  analyze  IL-6  promoter
activity (Figure 5). TGF-β1 increased the promoter activity of
the wild-type-reported plasmid about 2.5-fold above the no-
treatment control (p<0.001). However when the 3' or 5' end
of the AP-1-binding site of the IL-6 promoter was deleted, the
increased  promoter  activity  by  TGF-β1  was  significantly
attenuated (p<0.001). Our results indicate that the effect of
TGF-β1 on IL-6 expression is dependent on the AP-1-binding
site of the IL-6 promoter region and suggest that TGF-β1-
Figure 2. Multiplex reverse transcription PCR. Multiplex reverse
transcription PCR sets for interleukins (ILs; A, B) and housekeeping
genes (C). For each set of data, lane 1 represents the control group
with no transforming growth factor (TGF)-β1 treatment and lane 2
represents the study group with 10 ng/ml TGF-β1 treatment for 72
h. Lane M contains positive markers. GAPDH, glyceraldehyde-3-
phosphate  dehydrogenase;  IL-1RN,  interleukin-1  receptor
antagonist;  RPL13a;  SDHA,  succinate  dehydrogenase  complex
subunit  A;  β2M,  β2-microblobulin.  Two  asterisks  refer  to  a
significant increase (p<0.001) in expression of IL-6 and IL-11 in the
presence of TGF-β1.
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2125induced myofibroblast transdifferentiation is dependent, at
least in part, on TGF-β1-induced IL-6 expression.
Figure  3.  RNA  interference  assay  for  IL-6  and  IL-11.  After
administering small interfering RNAs targeting IL-6 (A) and IL-11
(B), fibroblasts were exposed to 10 ng/ml transforming growth factor
(TGF)-β1 for 72 h. Then, the expression of α-smooth muscle actin
(α-SMA)  was  evaluated  using  western  blots.  Densitimetric  data
represent  the  mean±SD  of  results  from  three  independent
experiments. The asterisks refer to a significant difference compared
to TGF-β treatment only (p<0.001).
DISCUSSION
Transdifferentiation of fibroblasts to myofibroblasts is at the
core of the fibrotic process. Although the fibrosis caused by
these  activated  fibroblasts  is  essential  for  natural  wound
healing, it can also result in excessive scarring, which is one
of the most common causes of surgical failure after various
ocular  surgeries,  including  glaucoma-filtering  procedures
[1-6]. Although adjunctive antimetabolites can suppress the
proliferation  of  fibroblasts  and  reduce  subconjunctival
fibrosis, the use of these compounds may result in serious
complications;  thus  a  new  treatment  strategy  to  prevent
excessive fibrosis is required.
In  various  organs,  including  the  lung  and  heart,
inflammation  is  known  to  result  in  the  development  of
Figure 4. Immunofluorescent analysis of the expression of α-smooth
muscle actin. A: No treatment control, B: 10 ng/ml transforming
growth factor (TGF)-β1 for 72 h, C: IL-6-specific small interfering
(si)RNA, D: IL-6-specific siRNA plus 10 ng/ml TGF-β1 for 72 h,
E: IL-11-specific siRNA, and F: IL-11-specific siRNA plus 10 ng/
ml TGF-β1 for 72 h. The secondary antibody was conjugated with
fluoroscein isothiocyanate, resulting in green fluorescence. Total
magnification was 400×.
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2126fibrosis; TGF-β seems to be at the center of this process
[15-18]. At the ocular surface, TGF-β plays a key role as a
potent fibrogenic cytokine [25-29]. It is thought to stimulate
the  chemotaxis  and  transdifferentiation  of  fibroblasts,
resulting in the overproduction of collagen, fibronectin, and
other  ECM  components.  Furthermore,  TGF-β  reduces  the
degradation of synthesized ECM through suppression of the
activity  of  matrix  metalloproteases  and  the  activation  of
protease inhibitors.
IL-6 is essentially a chemoattractant and stimulator of
lymphocytes  [30-33].  It  also  functions  as  a  pleiotropic
mediator  in  the  acute-phase  response  and  stimulates  the
differentiation and proliferation of various target cells [33].
IL-6  exerts  its  effects  through  the  Janus  kinase/signal
transducer  and  activator  of  transcription  (JAK/STAT)
pathway  [34].  Because  the  IL-6  receptor  does  not  have
intrinsic  tyrosine  kinase  activity,  when  IL-6  binds  to  the
extracellular ligand-binding domain of its receptor, members
of the JAK family are activated and phosphorylate the tyrosine
residues of the IL-6 receptor, which then act as docking sites
for the SH2 domains of STATs. IL-6-activated T lymphocytes
then secrete TGF-β and trigger the fibrotic cascade.
Consistent with a previous report that IL-6 participates
directly  in  the  transdifferentiation  of  Tenon’s  capsule
fibroblasts to myofibroblasts [35], in the present study we
verified the presence of autocrine IL-6 from activated Tenon’s
capsule fibroblasts.
Figure 5. Promoter deletion assay for interleukin-6 (IL-6). Three
recombinant plasmids, in which different fragments of the activator
protein-1 (AP-1)-binding site on the human IL-6 promoter were
deleted, were used. After transfection with each plasmid, fibroblasts
were incubated with 10 ng/ml transforming growth factor (TGF)-β1
for 72 h. The luciferase activity was then determined and expressed
as the percent of the no-TGF-β1 treatment control. Data represent
the mean±SD of results from three independent experiments. The
asterisks refer to a significant difference (p<0.001) compared to the
wild type.
We found that the transcription of IL-6 and IL-11 was
increased  by  TGF-β1  stimulation  in  human  Tenon’s
fibroblasts, and that this was accompanied by the upregulated
expression of α-SMA. When IL-6-specific siRNAs were used,
the TGF-β1-stimulated increase in expression of α-SMA was
blocked, but this did not occur when IL-11-specific siRNAs
were used. Our results indicate that autocrine IL-6 produced
as a result of TGF-β-stimulation of human Tenon’s fibroblasts
stimulates  the  transdifferentiation  of  these  fibroblasts  to
myofibroblasts,  which  is  thought  to  be  essential  for
subconjunctival  fibrosis.  Modulation  of  autocrine  IL-6
production might be useful as a novel therapeutic strategy for
controlling postoperative subconjunctival fibrosis.
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